Drug Trial Radar · NCT00303056
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Feb 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
590
Actual
Start
Feb 2006
Primary completion
Jul 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief relative to triamcinolone, to evaluate the safety of icatibant, to evaluate overall conditions of daily life after treatment with icatibant, to assess systemic exposure of icatibant following intra-articular injection.
Conditions
- Joint Disease
Interventions
HOE140 IcatibantDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain during activity, at rest and at night will be measured daily via an electronic patient diary (EPD) using a 100-unit visual analog scale (VAS).
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Administrative Office
Bridgewater, New Jersey
Administrative Office
Vienna, Austria
Administrative Office
Prague, Czechia
Administrative Office
Berlin, Germany
Administrative Office
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.